Andreas Felix Hottinger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andreas Felix Hottinger has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Krisztian Homicsko
Department of Oncology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland
2 shared publications L. Negretti
2 shared publicationsRita de Micheli
Department of Oncology
2 shared publicationsA B Aissa
Clinical Research Unit of the Foundation Dr Henri Dubois Ferriére Dinu Lipatti & Centre of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
1 shared publicationA Bodmer
Clinical Research Unit of the Foundation Dr Henri Dubois Ferriére Dinu Lipatti & Centre of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
1 shared publicationA. Bodmer
1 shared publication
Latest Publications
- Open Access
Immunotherapy in Glioblastoma: A Clinical Perspective
Glioblastoma is the most frequent and the most aggressive brain tumor. It is notoriously resistant to current treatments, and the prognosis remains dismal. Immunotherapies have revolutionized the treatment of numerous cancer types and generate great hope for glioblastoma, alas without success until now. In this review, the rationale underlying immune targeting of glioblastoma, as well as the challenges faced when targeting these highly immunosuppressive tumors, are discussed. Innovative immune-targeting strategies including cancer vaccines, oncolytic viruses, checkpoint blockade inhibitors, adoptive cell transfer, and CAR T cells that have been investigated in glioblastoma are reviewed. From a clinical perspective, key clinical trial findings and ongoing trials are discussed for each approach. Finally, limitations, either biological or arising from trial designs are analyzed, and strategies to overcome them are presented. Proof of efficacy for immunotherapy approaches remains to be demonstrated in glioblastoma, but our rapidly expanding understanding of its biology, its immune microenvironment, and the emergence of novel promising combinatorial approaches might allow researchers to finally fulfill the medical need for GBM patients.
Open AccessImmunotherapy in Glioblastoma: A Clinical Perspective
Glioblastoma is the most frequent and the most aggressive brain tumor. It is notoriously resistant to current treatments, and the prognosis remains dismal. Immunotherapies have revolutionized the treatment of numerous cancer types and generate great hope for glioblastoma, alas without success until now. In this review, the rationale underlying immune targeting of glioblastoma, as well as the challenges faced when targeting these highly immunosuppressive tumors, are discussed. Innovative immune-targeting strategies including cancer vaccines, oncolytic viruses, checkpoint blockade inhibitors, adoptive cell transfer, and CAR T cells that have been investigated in glioblastoma are reviewed. From a clinical perspective, key clinical trial findings and ongoing trials are discussed for each approach. Finally, limitations, either biological or arising from trial designs are analyzed, and strategies to overcome them are presented. Proof of efficacy for immunotherapy approaches remains to be demonstrated in glioblastoma, but our rapidly expanding understanding of its biology, its immune microenvironment, and the emergence of novel promising combinatorial approaches might allow researchers to finally fulfill the medical need for GBM patients.
- 8 September 2020
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 32 (6) , 640-649
Physical approaches to treat glioblastoma
Purpose of review: Glioblastoma (GBM) patients have a poor prognosis despite the use of modern synergistic multimodal treatment strategies, with a progression-free survival estimated at 7–8 months, a median survival of 14–16 months and 5-year overall survival of 9.8%. Recent findings: Physical methods hold the promise to act synergistically with classical treatments to improve the outcome of GBM patients. Fluorescent guided surgery with 5-aminolevulinic acid and tumor-treating fields therapy have already shown positive results in randomized phase III trials and have been incorporated in the standard management. Other techniques such as photodynamic therapy (PDT) and focused ultrasound, often combined whit microbubbles, are reaching clinical development. Summary: Several clinical trials to evaluate the feasibility and efficacy of ultrasound devices to disrupt the blood–brain barrier are ongoing. PDT enables the creation of a safety margin or treatment of non-resecable tumors. However, randomized trials are urgently required to validate the efficacy of these promising approaches. We aim to critically review physical approaches to treat GBM, focusing on available clinical trial data.
- 8 September 2020
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 32 (6) , 640-649
Physical approaches to treat glioblastoma
Purpose of review: Glioblastoma (GBM) patients have a poor prognosis despite the use of modern synergistic multimodal treatment strategies, with a progression-free survival estimated at 7–8 months, a median survival of 14–16 months and 5-year overall survival of 9.8%. Recent findings: Physical methods hold the promise to act synergistically with classical treatments to improve the outcome of GBM patients. Fluorescent guided surgery with 5-aminolevulinic acid and tumor-treating fields therapy have already shown positive results in randomized phase III trials and have been incorporated in the standard management. Other techniques such as photodynamic therapy (PDT) and focused ultrasound, often combined whit microbubbles, are reaching clinical development. Summary: Several clinical trials to evaluate the feasibility and efficacy of ultrasound devices to disrupt the blood–brain barrier are ongoing. PDT enables the creation of a safety margin or treatment of non-resecable tumors. However, randomized trials are urgently required to validate the efficacy of these promising approaches. We aim to critically review physical approaches to treat GBM, focusing on available clinical trial data.
- 22 October 2018
- Published by Elsevier in Annals of Oncology
- Vol. 30 (1) , 155-156
Leptomeningeal tumor response to combined MAPK/ERK inhibition in V600E-mutated gliomas despite undetectable CSF drug levels
A F Hottinger, D Bensaid, R De Micheli, B Moura, K Mokhtari, E Cardoso, A Idbaih, R Stupp; Leptomeningeal tumor response to combined MAPK/ERK inhibition in V60
- 22 October 2018
- Published by Elsevier in Annals of Oncology
- Vol. 30 (1) , 155-156
Leptomeningeal tumor response to combined MAPK/ERK inhibition in V600E-mutated gliomas despite undetectable CSF drug levels
A F Hottinger, D Bensaid, R De Micheli, B Moura, K Mokhtari, E Cardoso, A Idbaih, R Stupp; Leptomeningeal tumor response to combined MAPK/ERK inhibition in V60
- Open Access
- 1 March 2018
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 5 (2) , e439
Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis
- 1 March 2018
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 5 (2) , e439
Open AccessNatalizumab may control immune checkpoint inhibitor–induced limbic encephalitis
- Open Access
- 1 May 2014
- Published by Springer Nature in British Journal of Cancer
- Vol. 110 (11) , 2655-2661
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as a potent radiosensitizer by arresting cells in the most radiosensitive cell cycle phase. This phase I open-label, noncontrolled dose escalation study was performed to determine the safety and maximum tolerated dose (MTD) of Sb in combination with radiation therapy (RT) and temozolomide (TMZ) in 17 patients with newly diagnosed high-grade glioma. Patients were treated with RT (60 Gy in 2 Gy fractions) combined with TMZ 75 mg m(-2) daily, and Sb administered at three dose levels (200 mg daily, 200 mg BID, and 400 mg BID) starting on day 8 of RT. Thirty days after the end of RT, patients received monthly TMZ (150-200 mg m(-2) D1-5/28) and Sb (400 mg BID). Pharmacokinetic (PK) analyses were performed on day 8 (TMZ) and on day 21 (TMZ&Sb) (Clinicaltrials ID: NCT00884416). The MTD of Sb was established at 200 mg BID. Dose-limiting toxicities included thrombocytopenia (two patients), diarrhoea (one patient) and hypercholesterolaemia (one patient). Sb administration did not affect the mean area under the curve(0-24) and mean Cmax of TMZ and its metabolite 5-amino-imidazole-4-carboxamide (AIC). Tmax of both TMZ and AIC was delayed from 0.75 (TMZ alone) to 1.5 h (combined TMZ/Sb). The median progression-free survival was 7.9 months (95% confidence interval (CI): 5.4-14.55), and the median overall survival was 17.8 months (95% CI: 14.7-25.6). Although Sb can be combined with RT and TMZ, significant side effects and moderate outcome results do not support further clinical development in malignant gliomas. The robust PK data of the TMZ/Sb combination could be useful in other cancer settings.
- 1 May 2014
- Published by Springer Nature in British Journal of Cancer
- Vol. 110 (11) , 2655-2661
Open AccessPhase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as a potent radiosensitizer by arresting cells in the most radiosensitive cell cycle phase. This phase I open-label, noncontrolled dose escalation study was performed to determine the safety and maximum tolerated dose (MTD) of Sb in combination with radiation therapy (RT) and temozolomide (TMZ) in 17 patients with newly diagnosed high-grade glioma. Patients were treated with RT (60 Gy in 2 Gy fractions) combined with TMZ 75 mg m(-2) daily, and Sb administered at three dose levels (200 mg daily, 200 mg BID, and 400 mg BID) starting on day 8 of RT. Thirty days after the end of RT, patients received monthly TMZ (150-200 mg m(-2) D1-5/28) and Sb (400 mg BID). Pharmacokinetic (PK) analyses were performed on day 8 (TMZ) and on day 21 (TMZ&Sb) (Clinicaltrials ID: NCT00884416). The MTD of Sb was established at 200 mg BID. Dose-limiting toxicities included thrombocytopenia (two patients), diarrhoea (one patient) and hypercholesterolaemia (one patient). Sb administration did not affect the mean area under the curve(0-24) and mean Cmax of TMZ and its metabolite 5-amino-imidazole-4-carboxamide (AIC). Tmax of both TMZ and AIC was delayed from 0.75 (TMZ alone) to 1.5 h (combined TMZ/Sb). The median progression-free survival was 7.9 months (95% confidence interval (CI): 5.4-14.55), and the median overall survival was 17.8 months (95% CI: 14.7-25.6). Although Sb can be combined with RT and TMZ, significant side effects and moderate outcome results do not support further clinical development in malignant gliomas. The robust PK data of the TMZ/Sb combination could be useful in other cancer settings.
- Open Access
- 5 January 2014
- Published by Editorial Office of Chinese Journal of Cancer in Chinese Journal of Cancer
- Vol. 33 (1) , 32-39
Standards of care and novel approaches in the management of glioblastoma multiforme
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. Standard therapeutic approaches provide modest improvement in the progression-free and overall survival, necessitating the investigation of novel therapies. We review the standard treatment options for GBM and evaluate the results obtained in clinical trials for promising novel approaches, including the inhibition of angiogenesis, targeted approaches against molecular pathways, immunotherapies, and local treatment with low voltage electric fields.
- 5 January 2014
- Published by Editorial Office of Chinese Journal of Cancer in Chinese Journal of Cancer
- Vol. 33 (1) , 32-39
Open AccessStandards of care and novel approaches in the management of glioblastoma multiforme
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. Standard therapeutic approaches provide modest improvement in the progression-free and overall survival, necessitating the investigation of novel therapies. We review the standard treatment options for GBM and evaluate the results obtained in clinical trials for promising novel approaches, including the inhibition of angiogenesis, targeted approaches against molecular pathways, immunotherapies, and local treatment with low voltage electric fields.
- 1 September 2012
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 104, 33
SP-38: The Rational for Concomitant Radio- and Chemotherapy in Malignant Glioma. State of the Art and Future Perspectives
- 1 September 2012
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 104, 33
SP-38: The Rational for Concomitant Radio- and Chemotherapy in Malignant Glioma. State of the Art and Future Perspectives
- Open Access
- 1 September 2012
- Published by Elsevier in Annals of Oncology
- Vol. 23 (suppl_10) , x33-x40
Decision making and management of gliomas: practical considerations
Over the last decade, diagnostic options and introduction of novel treatments have expanded the armamentarium in the management of malignant glioma. Combined chemoradiotherapy has become the standard of care in glioblastoma up to the age of 70 years, while treatment in elderly patients or with lower grade glioma is less well defined. Molecular markers define different disease subtypes and allow for adapted treatment selection. This review focuses on simple questions arising in the daily management of patients.
- 1 September 2012
- Published by Elsevier in Annals of Oncology
- Vol. 23 (suppl_10) , x33-x40
Open AccessDecision making and management of gliomas: practical considerations
Over the last decade, diagnostic options and introduction of novel treatments have expanded the armamentarium in the management of malignant glioma. Combined chemoradiotherapy has become the standard of care in glioblastoma up to the age of 70 years, while treatment in elderly patients or with lower grade glioma is less well defined. Molecular markers define different disease subtypes and allow for adapted treatment selection. This review focuses on simple questions arising in the daily management of patients.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 2054
Phase l study of sorafenib in combination with radiation therapy and temozolomide for the first-line treatment of patients with high grade glioma.
2054 Background: Sorafenib (Sb), an oral dual-action Raf kinase and VEGFR inhibitor, inhibits tumor cell proliferation and angiogenesis. Sb may further act as a potent radiosensitizer as it causes a time- and concentration-dependent arrest in G1, the most radiosensitive cell cycle phase. We conducted a phase I study to determine the safety and MTD of Sb in combination with radiation therapy and temozolomide (TMZ) as first line treatment of patients with high-grade gliomas. Methods: A traditional 3+3 dose escalation schema was employed. Patients were treated with radiation therapy (RT) to 60 Gy in 2 Gy fractions with TMZ 75 mg/m2 daily and Sb administered at 3 dose levels (DL1: 200 mg Sb daily, DL2: 200 mg Sb BID, DL3: 400 mg Sb BID) starting on day 8 of RT. Thirty days after the end of RT, patients were treated with monthly maintenance TMZ (150-200 mg/m2 D1-5/28) and Sb (400 mg BID). PK analyses were performed on day 8 for TMZ and day 21 for TMZ and Sb. Results: To date 14/15 planned patients with GBM have completed treatment. M/F: 5/9, median age: 52 years (range: 38-70). 6 patients have been treated at DL1 with 1 dose limiting toxicity (DLT) consisting of grade 4 pulmonary embolism, 5 at DL2 without DLT and 3 at DL3 with 2 DLTs (grade 4 dyslipidemia and grade 4 thrombocytopenia). The most common drug-related toxicities were thrombocytopenia (4 patients), fatigue (4), hypertension (4), hand-foot skin syndrome (3), skin reactions (3), leucopenia (1), constipation (1) and diarrhea (1). Geometric mean (GM) of Cmax of T were 6.18 (SD: 1.40) mg/L on day 8 (T alone) and 6.22 (1.79) mg/L on day 21 (T+S). GM of AUC(0-24) of T were 11.9 (1.18) mg*h/L and 13.6 (1.19) mg*h/L on day 8 and 21 respectively. GM of Cmax and AUC(0-12) for S on day 21 were 2.54 (1.95) mg/L and 19.8 (1.69) mg*h/L respectively. Studies for the other DLs are ongoing. Conclusions: The combination of Sb with RT and TMZ is safe and well tolerated at a dose of 200 mg Sb BID + 75 mg TMZ daily. PK parameters indicated that Sb had no effect on the bioavailability of TMZ. Outcome results will be available at the meeting.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , 2054
Phase l study of sorafenib in combination with radiation therapy and temozolomide for the first-line treatment of patients with high grade glioma.
2054 Background: Sorafenib (Sb), an oral dual-action Raf kinase and VEGFR inhibitor, inhibits tumor cell proliferation and angiogenesis. Sb may further act as a potent radiosensitizer as it causes a time- and concentration-dependent arrest in G1, the most radiosensitive cell cycle phase. We conducted a phase I study to determine the safety and MTD of Sb in combination with radiation therapy and temozolomide (TMZ) as first line treatment of patients with high-grade gliomas. Methods: A traditional 3+3 dose escalation schema was employed. Patients were treated with radiation therapy (RT) to 60 Gy in 2 Gy fractions with TMZ 75 mg/m2 daily and Sb administered at 3 dose levels (DL1: 200 mg Sb daily, DL2: 200 mg Sb BID, DL3: 400 mg Sb BID) starting on day 8 of RT. Thirty days after the end of RT, patients were treated with monthly maintenance TMZ (150-200 mg/m2 D1-5/28) and Sb (400 mg BID). PK analyses were performed on day 8 for TMZ and day 21 for TMZ and Sb. Results: To date 14/15 planned patients with GBM have completed treatment. M/F: 5/9, median age: 52 years (range: 38-70). 6 patients have been treated at DL1 with 1 dose limiting toxicity (DLT) consisting of grade 4 pulmonary embolism, 5 at DL2 without DLT and 3 at DL3 with 2 DLTs (grade 4 dyslipidemia and grade 4 thrombocytopenia). The most common drug-related toxicities were thrombocytopenia (4 patients), fatigue (4), hypertension (4), hand-foot skin syndrome (3), skin reactions (3), leucopenia (1), constipation (1) and diarrhea (1). Geometric mean (GM) of Cmax of T were 6.18 (SD: 1.40) mg/L on day 8 (T alone) and 6.22 (1.79) mg/L on day 21 (T+S). GM of AUC(0-24) of T were 11.9 (1.18) mg*h/L and 13.6 (1.19) mg*h/L on day 8 and 21 respectively. GM of Cmax and AUC(0-12) for S on day 21 were 2.54 (1.95) mg/L and 19.8 (1.69) mg*h/L respectively. Studies for the other DLs are ongoing. Conclusions: The combination of Sb with RT and TMZ is safe and well tolerated at a dose of 200 mg Sb BID + 75 mg TMZ daily. PK parameters indicated that Sb had no effect on the bioavailability of TMZ. Outcome results will be available at the meeting.
- Open Access
- 1 April 2011
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 4 (1) , 211-215
Delayed but Complete Response following Oral Temozolomide Treatment in Melanoma Leptomeningeal Carcinomatosis
Isolated leptomeningeal recurrence of melanoma is rare, occurring in 2% of patients with central nervous system involvement secondary to melanoma. The optimal treatment of leptomeningeal carcinomatosis (LMC) in melanoma has not yet been determined and remains a major challenge. We report a melanoma patient who presented with isolated LMC in the form of a new-onset weakness of the lower limbs, paresthesia of the left hand and foot, lumbago and headache. A lumbar puncture and spinal MRI confirmed LMC. The patient was treated with temozolomide 75 mg/m2/day on a 4 weeks on/2 weeks off schedule. After an initial transient clinical deterioration, the patient showed a complete radiological response as well as a dramatic improvement in quality of life. The encouraging clinical response reported here suggests that dose-intensified temozolomide might have significant activity in the treatment of leptomeningeal dissemination of melanoma and may be a valid treatment option for patients who have not been previously exposed to this agent. Moreover, this treatment regimen is extremely well tolerated and obviates the need for repeated intrathecal administrations of chemotherapeutic agents, which are often not well tolerated by patients who have significant co-morbidities due to their disease. As illustrated in this case, response to temozolomide may occur in a delayed manner, highlighting the importance of following temozolomide treatment long enough before determining that it is inefficient in a given patient.
- 1 April 2011
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 4 (1) , 211-215
Open AccessDelayed but Complete Response following Oral Temozolomide Treatment in Melanoma Leptomeningeal Carcinomatosis
Isolated leptomeningeal recurrence of melanoma is rare, occurring in 2% of patients with central nervous system involvement secondary to melanoma. The optimal treatment of leptomeningeal carcinomatosis (LMC) in melanoma has not yet been determined and remains a major challenge. We report a melanoma patient who presented with isolated LMC in the form of a new-onset weakness of the lower limbs, paresthesia of the left hand and foot, lumbago and headache. A lumbar puncture and spinal MRI confirmed LMC. The patient was treated with temozolomide 75 mg/m2/day on a 4 weeks on/2 weeks off schedule. After an initial transient clinical deterioration, the patient showed a complete radiological response as well as a dramatic improvement in quality of life. The encouraging clinical response reported here suggests that dose-intensified temozolomide might have significant activity in the treatment of leptomeningeal dissemination of melanoma and may be a valid treatment option for patients who have not been previously exposed to this agent. Moreover, this treatment regimen is extremely well tolerated and obviates the need for repeated intrathecal administrations of chemotherapeutic agents, which are often not well tolerated by patients who have significant co-morbidities due to their disease. As illustrated in this case, response to temozolomide may occur in a delayed manner, highlighting the importance of following temozolomide treatment long enough before determining that it is inefficient in a given patient.